Norpramin (desipramine hydrochloride) - Dear Healthcare Professional Letter:Risk of sudden death and cardiac dysrhythmias

[FDA MedWatch <fda@xxxxxxxxxxxxxxxxxxxxxxx>]

Title: Norpramin (desipramine hydrochloride) - Dear Healthcare Professional Letter:Risk of sudden death and cardiac dysrhythmias

Norpramin (desipramine hydrochloride) - Dear Healthcare Professional Letter

Audience: Psychiatric healthcare professionals

Sanofi-Aventis and FDA notified healthcare professionals of changes to the Warnings and Overdosage sections of the Prescribing Information for Norpramin (desipramine hydrochloride), indicated for the treatment of depression. The new safety information states that extreme caution should be used when this drug is given to patients who have a family history of sudden death, cardiac dysrhythmias, and cardiac conduction disturbances; and that seizures precede cardiac dysrhythmias and death in some patients.

Read the complete MedWatch 2009 Safety summary, including a link to the Dear Healthcare Professional letter, at:

http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm192655.htm

---

Manage your FDA Subscriptions:

• Update your preferences or unsubscribe
• Questions about this service? support@xxxxxxxxxxxxxxx
• Other inquiries? webmail@xxxxxxxxxx

GovDelivery, Inc. sending on behalf of U.S. Food & Drug Administration (FDA) · 5600 Fishers Lane · Rockville MD 20857 · 800-439-1420